



Medical Director

Y-mAbs Therapeutics A/S (Y-mAbs) is now looking for a Medical Director.

In this newly established position you will report to the SVP, Chief Medical Officer.

YmAbs is a clinical stage biopharmaceutical company, public listed on Nasdaq and focused on developing new cancer treatments through immunotherapies. Our company focus and most advanced programs are confined within pediatric oncology. In addition to clinical programs, Y-mAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies.

Y-mAbs is facing an exciting time, with initiation of new clinical trials in both Europe and US this year. Y-mAbs has started a rolling submission (BLA) on our lead program; Naxitamab and expect to submit another BLA later this year on our second lead program; Omburtamab. Our innovative pipeline is expected to result in more clinical activity in 2020 including clinical trials with bi-specific antibodies. YmAbs has activities spanning from early stage development through pivotal clinical trials, planned license application submission(s), product approval(s) and beyond.

As our new Medical Director your will oversee the direction, planning, execution, and interpretation of clinical trials of one or more clinical programs. You will participate in cross-functional teams to generate, deliver, and interpret high-quality clinical data supporting overall product strategy.

Also, a key role is to expand and maintain high quality international KOL network within relevant areas. You will also be part of medical evaluations of new target proposals and responsible for designing new clinical programs including First-in-Human clinical studies as well as pivotal trials. Y-mAbs operates with an outsourcing model using an external CRO, however full medical oversight is mandatory, thus close collaboration with external the CRO is an integrated part of the position.

Key responsibilities:

- Provide medical expertise and therapeutic knowledge within field on oncology including keep awareness over latest research and competitive landscape
- Manages the design and implementation of one or more clinical development programs in support of an overall Product Development Plan, based on strong medical and scientific principles
- Developing and maintaining international Key Opinion Leader relationships
- Medical resource for cross functional teams

Personal and professional qualifications:

- 5+ years' experience in industry (R&D Medical position)
- Experience in First-in-Human clinical trials an advantage
- Medical Doctor (MD). Completion of a residency program strongly preferred. Completion of a subspecialty fellowship within oncology is desirable
- Prior experience with Health Authority meetings an advantage
- Prior experience working with CROs an advantage



- Previous experience establishing and maintaining external KOL network
- We expect you to have an entrepreneurial mindset
- Demonstrates initiative and capacity to work under pressure
- As a team player, you can work with ambitious timelines in our slim organization with a cross-functional team
- You are result-oriented and committed to contributing to the overall success of YmAbs
- Ability to communicate complex clinical issues and analysis orally and in writing
- Our company language is English, so your communication in both written and spoken English is fluent

Y-mAbs offers:

- An exciting work environment where challenging assignments will come your way
- Great office location in Hørsholm including canteen, public transport and easy parking

For more details about the job or our company, please see our homepage www.ymabs.com In case of further information needed, contact Steen Lisby, SVP, Chief Medical Officer, at +45 23223140.

Please note that all applications must be marked with position ID number: 1001, submitted in English to : hr@ymabs.com and will be treated confidentially.

Y-mAbs Therapeutics A/S is a Danish affiliate of Y-mAbs Therapeutics Inc., which is located in New York. Our mission is to discover, develop and deliver novel antibody therapeutics for the treatment of both pediatric and adult cancer patients.